The Food and Drug Administration has approved a first-of-its-kind cholesterol pill that could expand treatment options for millions of Americans at high risk of heart disease. The medication, developed by Merck and marketed as Lipfendra, is the first oral drug that blocks the PCSK9 protein. That target has previously been treated only with injectable medications.

The approval is intended for patients whose LDL, often called "bad" cholesterol, remains too high despite taking statins, the standard drugs used to reduce the risk of heart attacks and strokes. By blocking the PCSK9 protein, the medication helps the body remove more cholesterol from the bloodstream.

In clinical trials involving thousands of high-risk patients, those who added Lipfendra to their existing treatment saw LDL cholesterol levels fall by more than 55% after six months. The reduction remained largely intact after one year, while side effects such as dizziness and diarrhea occurred at rates similar to those seen in patients taking a placebo.

The FDA approved the drug through its expedited review program for promising new therapies that address significant public health needs.

Heart disease is the leading cause of death in the United States for men and women, and high LDL cholesterol is one of its biggest risk factors. While statins are effective for many patients, they do not lower cholesterol enough for everyone, particularly those with existing heart disease or a very high risk of heart attack or stroke.

The approval of an oral PCSK9 medication gives doctors another treatment option for patients who need greater cholesterol reduction without relying on injections. The new pill could also improve access to a class of medications that has been underused for years. Injectable PCSK9 drugs have often been limited by high prices, insurance restrictions, and patient reluctance to use regular injections.

An oral alternative may be easier for patients to take and for physicians to prescribe, potentially allowing more high-risk Americans to reach recommended cholesterol levels. If that leads to wider use, it could help prevent future heart attacks and strokes while reducing some of the long-term costs associated with cardiovascular disease.

For Americans with high cholesterol, especially those who have suffered a heart attack or been diagnosed with heart disease, this approval could give them another option if statins alone are not enough. Instead of adding an injectable medication, eligible patients may be able to take a daily pill that delivers a similar type of cholesterol reduction. That could make treatment easier for people who dislike injections or have trouble keeping up with them.

The medication is designed to complement statins rather than replace them, giving doctors another option when cholesterol remains too high despite standard treatment. Access and availability will largely depend on coverage and pricing. Should coverage become widespread, the pill could very well make this type of advanced cholesterol treatment more practical for many high-risk patients by offering an alternative to regular injections while helping reduce the risk of heart attacks and strokes.